New hope for men with advanced prostate cancer: radioactive drug trial seeks to control disease after other treatments fail

This trial is testing a new radioactive drug called Actinium rhPSMA-10.1 for men with advanced prostate cancer that has spread and stopped responding to standard hormone treatments. The drug is designed to find and destroy prostate cancer cells throughout the body using targeted radiation. Researchers will give the drug every six weeks to up to 60 men to find the safest dose and see how well it controls the cancer, particularly in those who previously benefited from a similar treatment called Lutetium-PSMA.